The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.

Age-related macular degeneration Avacincaptad pegol C3 C5 Complement Eculizumab Geographic atrophy Living systematic review Meta-analysis Pegcetacoplan

Journal

Survey of ophthalmology
ISSN: 1879-3304
Titre abrégé: Surv Ophthalmol
Pays: United States
ID NLM: 0404551

Informations de publication

Date de publication:
24 Nov 2023
Historique:
received: 02 05 2023
revised: 14 11 2023
accepted: 20 11 2023
pubmed: 27 11 2023
medline: 27 11 2023
entrez: 26 11 2023
Statut: aheadofprint

Résumé

With the introduction of therapies to treat geographic atrophy (GA), GA management in clinical practice is now possible. A living systematic review can provide access to timely and robust evidence synthesis. This review found that complement factor 3 and 5 (C3 and C5) inhibition compared to sham likely reduces change in square root GA area at 12 months and untransformed GA area at 24 months. There is likely little to no difference in the rate of systemic treatment-emergent adverse events compared to sham. C3 and C5 inhibition, however, likely does not improve best-corrected visual acuity (BCVA) at 12 months, and the evidence is uncertain regarding change in BCVA at 24 months. Higher rates of ocular treatment emergent adverse effects with complement inhibition occur at 12 months and likely at 24 months. Complement inhibition likely results in new onset neovascular age-related macular degeneration at 12 months. This living meta-analysis will continuously incorporate new evidence.

Identifiants

DOI: 10.1016/j.survophthal.2023.11.008 PMID: 38008405
pubmed: 38008405
pii: S0039-6257(23)00160-1
doi: 10.1016/j.survophthal.2023.11.008
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Anubhav Garg (A)

Division of Ophthalmology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.

Keean Nanji (K)

Division of Ophthalmology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.

Felicia Tai (F)

Division of Ophthalmology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.

Mark Phillips (M)

Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.

Dena Zeraatkar (D)

Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.

Sunir J Garg (SJ)

Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, PA, USA.

SriniVas R Sadda (SR)

Department of Ophthalmology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA; Doheny Eye Institute, Los Angeles, CA, USA.

Peter K Kaiser (PK)

Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.

Robyn H Guymer (RH)

Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia; Department of Surgery (Ophthalmology), University of Melbourne, Melbourne, Australia.

Sobha Sivaprasad (S)

Institute of Ophthalmology, University College London, UK; NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.

Charles C Wykoff (CC)

Retina Consultants of Texas, Houston, TX, USA; Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA.

Varun Chaudhary (V)

Division of Ophthalmology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada. Electronic address: vchaudh@mcmaster.ca.

Classifications MeSH